High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 6, 2014, Pages 2349-2354

  Mathews Griner, Lesley A ^a   Guha, Rajarshi ^a   Shinn, Paul ^a   Young, Ryan M ^b   Keller, Jonathan M ^a   Liu, Dongbo ^a   Goldlust, Ian S ^a   Yasgar, Adam ^a   McKnight, Crystal ^a   Boxer, Matthew B ^a   Duveau, Damien Y ^a   Jiang, Jian Kang ^a   Michael, Sam ^a   Mierzwa, Tim ^a   Huang, Wenwei ^a   Walsh, Martin J ^a   Mott, Bryan T ^a   Patel, Paresma ^a,b   Leister, William ^a   Maloney, David J ^a   Leclair, Christopher A ^a   Rai, Ganesha ^a   Jadhav, Ajit ^a   Peyser, Brian D ^c   Austin, Christopher P ^a   Martin, Scott E ^a   Simeonov, Anton ^a   Ferrer, Marc ^a   Staudt, Louis M ^b   Thomas, Craig J ^b   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Imbruvica; PCI 32765; Translational research

Indexed keywords

IMBRUVICA; PCI-32765; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHATIDYLINOSITOL 3-KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84893825160     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311846111     Document Type: Article

References (52)

1. Coiffier B, et al. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12):2040-2045.
2. Al-Lazikani B, Banerji U, Workman P (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30(7):679-692.
3. Kummar S, et al. (2010) Utilizing targeted cancer therapeutic agents in combination: Novel approaches and urgent requirements. Nat Rev Drug Discov 9(11):843-856.
4. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
5. Garnett MJ, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570-575.
6. Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13):4808-4817.
7. Flaherty KT, et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694-1703.
8. US Food and Drug Administration (2010) Guidance for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combination. Available at www. fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM236669.pdf. Accessed June 2013.
9. Young RM, Staudt LM (2013) Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12(3):229-243.
10. Davis RE, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-92.
11. Lenz G, et al. (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676-1679.
12. Ngo VN, et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115-119.
13. Yang Y, et al. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6):723-737.
14. Lam LT, et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111(7):3701-3713.
15. Borisy AA, et al. (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100(13):7977-7982.
16. Small BG, et al. (2011) Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol 7(12):902-908.
17. Lehár J, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659-666.
18. Lehár J, Stockwell BR, Giaever G, Nislow C (2008) Combination chemical genetics. Nat Chem Biol 4(11):674-681.
19. Ellson R, et al. (2003) Transfer of low nanoliter volumes between microplates using focused acoustics-Automation considerations. J Lab Auto 8(3):29-34.
20. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585-615.
21. Grabovsky Y, Tallarida RJ (2004) Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles. J Pharmacol Exp Ther 310(3):981-986.
22. Lehár J, et al. (2007) Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 3:80.
23. Cokol M, et al. (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7:544.
24. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861-1874.
25. Rosenwald A, Staudt LM (2003) Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 44(Suppl 3):S41-S47.
26. Compagno M, et al. (2009) Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 459(7247):717-721.
27. Staudt LM (2010) Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2(6):a000109.
28. Miller SC, et al. (2010) Identification of known drugs that act as inhibitors of NFkappaB signaling and their mechanism of action. Biochem Pharmacol 79(9):1272-1280.
29. Alzani R, et al. (2010) Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Exp Hematol 38(4):259-269, e2.
30. Qing G, Yan P, Xiao G (2006) Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res 16(11):895-901.
31. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr. (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270(5234):283-286.
32. Jane EP, Premkumar DR, Pollack IF (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kappaB signaling pathway. Mol Cancer Ther 10(1):198-208.
33. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D (2006) Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 281(47):35764-35769.
34. Kaileh M, et al. (2007) Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 282(7):4253-4264.
35. Alizadeh AA, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503-511.
36. Lenz G, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105(36):13520-13525.
37. Kloo B, et al. (2011) Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 108(1):272-277.
38. Lannutti BJ, et al. (2011) CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2):591-594.
39. Maira S-M, et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11(2):317-328.
40. Maira S-M, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851-1863.
41. Wallin JJ, et al. (2011) GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10(12):2426-2436.
42. Hirai H, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956-1967.
43. Atkins MB, Yasothan U, Kirkpatrick P (2009) Everolimus. Nat Rev Drug Discov 8(7): 535-536.
44. Hoellenriegel J, et al. (2012) Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-1583.
45. Oltersdorf T, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677-681.
46. Souers AJ, et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202-208.
47. Wilson WH, et al.; Cancer Leukemia Group B (2012) A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97(5):758-765.
48. Advani RH, et al. (2012) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B cell malignancies. J Clin Oncol 42:7906-7915.
49. Wilson WH, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study. 54th Annual Meeting and Exposition, December 2012 (American Society of Hematology, Atlanta, GA), abstr 686.
50. Byrd JC, et al. (2012) The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: New and updated results of 116 patients in a phase Ib/II study. 54th Annual Meeting and Exposition, December 2012 (American Society of Hematology, Atlanta, GA), abstr 189.
51. Wilson WH, et al. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11(12):1149-1159.
52. McCool KW, Miyamoto S (2012) DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunol Rev 246(1):311-326.